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Oral calcitriol is associated  
with improved survival  
in non-dialyzed CKD patients
Multiple studies demonstrate an association between the use of 
intravenous vitamin D and better outcomes among patients with 
end-stage renal disease (ESRD). These outcomes include shorter 
hospital stays and lower mortality rates.1,2 Further, the concentra-
tion of endogenously produced vitamin D is also directly associ-
ated with survival in incident dialysis patients.3
A new retrospective cohort study examined whether or not 
oral calcitriol improved survival in chronic kidney disease (CKD) 
patients. Shoben et al. used data from multiple sources in the Veter-
ans Administration health-care system in the Pacific Northwest to 
compare two groups, one that took oral calcitriol and another that 
was as similar as possible but did not take oral calcitriol. Adjusted 
for age, race, and sex, calcitriol use was associated with a 24% lower 
hazard of death and a 14% lower hazard of death or initiation of 
long-term dialysis as compared with no calcitriol use (hazard ratio 
= 0.76, confidence interval 0.60–0.95, P = 0.014, and hazard ratio = 
0.86, confidence interval 0.71–1.04, P = 0.120, respectively). Until 
randomized trials are performed, these data strongly support the 
treatment of secondary hyperparathyroidism in CKD in a manner 
similar to the way we approach the complication in ESRD patients. 
They further support the conclusion that intravenous therapy is 
not essential and that oral therapy may provide benefit. (J Am Soc 
Nephrol 2008; 19: 1613–1619; doi:10.1681/ASN.2007111164)
Lynda Szczech
1 N Engl J Med 2003; 349: 446–456. 2J Am Soc Nephrol 2005; 16: 1115–1125. 3Kidney Int 
2007; 72: 1004–1013.
An experimental model of acute 
humoral rejection of renal allografts
Improvements in acute rejection prophylaxis after kidney trans-
plantation have drastically reduced the incidence of acute cellular 
rejection. Yet the prophylaxis for and treatment of alloantibody-
mediated acute humoral rejection (AHR) remains in its infancy. 
AHR is associated with poor clinical outcomes and, in human renal 
allografts, is mainly characterized by the presence of diffuse C4d 
deposition along the peritubular capillaries. The current criteria 
for AHR include (1) the presence of donor-specific antibodies; 
(2) the diffuse deposition of C4d in the peritubular capillaries; (3) 
histological evidence of tissue injury; and (4) clinical evidence of 
graft dysfunction. Up to 8% of renal transplant patients experi-
ence AHR, which includes a majority of cases that are resistant 
to traditional therapy for acute rejection. Furthermore, AHR is 
frequently found to coexist with acute cellular rejection. Preexist-
ing alloantibodies due to blood transfusion, pregnancy, or previous 
transplantation are present in 25% of the United States popula-
tion. These alloantibodies represent a significant impediment to 
transplantation in many instances. To allow such patients to receive 
a transplant, the antibodies are removed from the peripheral cir-
culation before transplantation, a method known as desensitiza-
tion. This is not uniformly successful and commonly leads to a 
rebound in antibody production after transplantation. Efforts to 
reverse AHR and limit its damage to the kidney are limited because 
clinicians lack understanding of its underlying mechanisms. In a 
recent article, Bickerstaff et al. found that presensitization of recipi-
ents with donor skin grafts resulted in rejection of subsequent renal 
allografts in a mouse kidney transplant model. All presensitized 
mice developed renal failure an average of 8 days after the graft 
with elevated serum creatinine. The histology of the graft showed 
mild, diffuse, interstitial, mononuclear-cell infiltrates; prominent 
peritubular capillary inflammatory-cell margination; patchy inter-
stitial hemorrhage; interstitial edema; and focal glomerular fibrin 
deposition. Because anti-mouse C4d antibodies were not available, 
C3d-reactive antibodies were used to detect complement deposi-
tion; C3d deposition was diffuse and prominent in peritubular cap-
illaries (Figure). The authors found high levels in sera of circulating 
alloantibodies, which had broad cross-reactivity to many major 
histocompatibility complex haplotypes. The clinical phenotype and 
histological findings of this model are frequently associated with 
cellular rejection, as are those of human renal allograft recipients, 
and they strongly resemble AHR. This animal model thus provides 
a valuable tool to study the pathogenesis of AHR, its relationship 
to cellular alloimmunity, its contribution to graft injury, and the 
effects of various potential therapeutic interventions. (Am J Pathol 
2008; 173: 347–357; doi:10.2353/ajpath.2008.070391)
Juan Oliver
Renal Cd36 as a determinant  
of blood pressure
The kidney, involved in the pathogenesis of all mendelian disor-
ders of blood pressure regulation so far described, is believed to 
have a critical role in the development of essential hypertension. 
Immunofluorescence for C3d. (a) Diffuse strong C3d staining within 
the peritubular capillaries of rejected renal allografts of presensitized 
recipients. Arrows point to the positive staining in the capillaries.  
(b) C3d staining is absent in the capillaries of renal allografts of non-
sensitized recipients. There is tubular basement membrane C3d staining, 
which is a nonspecific finding and was seen in most animals.
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Essential hypertension, the most prevalent form of hypertension, 
is caused by complex interactions of multiple environmental and 
genetic factors. In a previous publication,1 Hubner et al. used 
recombinant inbred rat strains derived from the spontaneously 
hypertensive rat (SHR) and the normotensive Brown Norway 
rat. They conducted expression quantitative trait locus (eQTL) 
analysis of the kidney by mapping chromosome regions linked to 
renal expression of 15,923 transcripts. Linkage analysis showed 
2490 expression quantitative trait loci in the kidney at a genome-
wide statistically significant level. Of these, 780 loci were con-
sidered to be regulated in cis by virtue of each having its linkage 
peak within close proximity (10 Mbp) of the physical location 
of the probe set used to identify its transcript. To identify high-
priority candidate genes for blood pressure regulation, Pravenec 
et al. have now carried out quantitative trait transcripts analy-
sis (that is, of whether transcript abundance is associated with 
phenotype) of the kidney and integrated it with renal expression 
profiles and blood pressure. They found that the renal expression 
of Cd36, the gene encoding the CD36 fatty acid transporter, cor-
related inversely with both systolic and diastolic blood pressures. 
In addition, the recombinant inbred strains inheriting the SHR 
variant of Cd36 showed greater systol ic and diastolic pressures 
than the recombinant inbred strains inheriting the Brown Nor-
way rat variant of Cd36. To determine whether selective lack of 
wild-type Cd36 in the kidney might be sufficient to promote 
increased blood pressure, the authors carried out a variety of 
renal transplantation experiments using donor kidneys from 
either the SHR progenitor, which lacks wild-type Cd36, or the 
SHR-TG19 transgenic strain, which has robust renal expression 
of wild-type Cd36. The blood pressure of recipients that received 
a donor kidney lacking wild-type Cd36 was significantly greater 
than the blood pressure of recipients that received a donor kid-
ney expressing wild-type Cd36 (Figure). These results are con-
sonant with the observation that mice with targeted deletion of 
CD36 have slightly higher blood pressure than controls.
CD36 deficiency occurs in 3% of Asian and African subjects 
but in less than 0.3% of Americans of European descent. CD36 is 
expressed in several regions of the kidney, including on capillary 
endothelium; it is also known to colocalize with endothelial nitric 
oxide synthase and determines its activation by fatty acids. Thus, 
the findings in spontaneously hypertensive rats, Cd36 knockout 
mice, and humans all demonstrate a role for Cd36 in the genetic 
control of blood pressure and that its deficiency in the kidney is a 
genetically determined risk factor for spontaneous hypertension. 
(Nat Genet 2008; 40: 952–954; doi:10.1038/ng.164)
Juan Oliver
1Nat Genet 2005; 37: 243–253; doi:10.1038/ng1522.
How tissue transglutaminase 
contributes to  
interstitial renal fibrosis
Renal fibrosis, the final pathway common among many types of 
kidney diseases, is defined by an exaggerated accumulation of 
extracellular matrix proteins. Tissue transglutaminase (TG2) 
weakens the stability of extracellular matrix proteins and makes 
the extracellular matrix resistant to degradation. In addition, 
TG2 also activates transforming growth factor-β (TGF-β). 
Shweke et al. investigated the role of TG2 in the development 
of renal fibrosis using mice with a knockout of the TG2 gene 
(KO). The mice were studied at baseline and 12 days after uni-
lateral ureteral obstruction, which significantly increased inter-
stitial TG2 expression in wild-type mice (P < 0.001). Interstitial 
fibrosis was evident in both groups, but total and fibrillar col-
lagen was considerably lower in KO mice compared with wild-
type mice (P < 0.001) (Figure). Similarly, mRNA and protein 
expression of collagen I was significantly lower in KO animals 
(P < 0.05). A statistically significant reduction in renal 
inflammation and fewer myofibroblasts occurred in KO mice 
(P < 0.01). Free active TGF-β decreased in KO mice (P < 0.05), 
although total (active plus latent) TFG-β concentration did 
not change between groups. These results show that mice defi-
cient in TG2 are protected against the development of fibrotic 
lesions in obstructive nephropathy. This protection can be 
explained by reduced macrophage and myofibroblast infiltra-
tion, as well as a decreased rate of collagen I synthesis because 
of decreased TGF-β activation. These results suggest that 
inhibiting TG2 may offer a new therapy for the progression of 
renal fibrosis. (Am J Pathol 2008;173: 631–642; doi:10.2353/
ajpath.2008.080025)
Marc De Broe
Daily systolic blood pressure in 10-week-old bilaterally nephrectomized 
male SHR congenic rats that received a donor kidney from either the SHR 
congenic strain expressing wild-type Cd36 (+WT Cd36, filled circles) or the SHR 
progenitor strain that lacks wild-type Cd36 (–WT Cd36, open circles).
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Representative example of renal fibrillar collagen content revealed by red 
Sirius staining and polarized light in wild-type (WT) and TG2 KO mice (KO), 
after unilateral ureteral obstruction.
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